Format

Send to

Choose Destination
See comment in PubMed Commons below
Stem Cell Res. 2014 Jan;12(1):132-8. doi: 10.1016/j.scr.2013.10.001. Epub 2013 Oct 10.

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD.

Author information

1
Department of Hematology, The First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100048, China.
2
Department of Hematology, The First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100048, China. Electronic address: xiongwuxiao@sohu.com.
3
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
4
TEDA Research Center of Life Science and Technology, State Key Laboratory of Experimental Hematology, Institute of Hematology, Tianjin 300020, China.

Abstract

Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immunesuppressive effects. We cotransplanted the culture-expanded third-party donor-derived umbilical cord MSCs (UC-MSCs) in 21 young people with severe aplastic anemia (SAA) undergoing haplo-HSCT without T-cell-depleted. We observed that all patients had sustained hematopoietic engraftment without any adverse UC-MSC infusion-related events. Furthermore, we did not observe any increase in severe aGVHD. These data suggest that UC-MSCs, possibly thanks to their potent immunosuppressive effect on allo-reactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure and severe GVHD in haplo-HSCT.

PMID:
24185180
DOI:
10.1016/j.scr.2013.10.001
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center